ArticleEuropean journal of nuclear medicine and molecular imaging2017
Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers.
Article in European journal of nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 11 citations in OpenAlex.
- The application ofQuantitative imaging in medicine and surgery · 2023Review
- Metabolic Tumor Volume Measured byJournal of hepatocellular carcinoma · 2023Article
- CMBD: a manually curated cancer metabolic biomarker knowledge database.Database : the journal of biological databases and curation · 2021Article
- Imaging characteristics and prognostic values of hepatic epithelioid hemangioendothelioma onClinical and experimental medicine · 2020Article
- Predicting tumor recurrence using metabolic indices ofOncology letters · 2020Article
- Added Value of Contrast Medium in Whole-Body Hybrid Positron Emission Tomography/Magnetic Resonance Imaging: Comparison between Contrast-Enhanced and Non-Contrast-Enhanced Protocols.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2020Article
- Transcriptomics Associates Molecular Features withCancer research · 2019Article
- Impact of the EARL harmonization program on automatic delineation of metabolic active tumour volumes (MATVs).EJNMMI research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
Abstract
purpose
methodsWe retrospectively analyzed the records of patients with HCC who underwent FDG PET/CT before initial treatment from May 2013 through May 2014. Four PET/CT parameters were measured: maximum standardized uptake value (SUV
resultsThe analysis included 56 patients. Univariate analysis of the association between OS and continuous variables, including the PET/CT parameters SUV
conclusionPretreatment FDG PET/CT in patients with HCC can add to the prognostic value of standard clinical measures. Incorporation of imaging biomarkers derived from FDG PET/CT into HCC staging systems should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.